Parallel, Double-dummy, Superiority Study Levocetirizine/Pseudoephedrine x Zina for Allergic Rhinitis in Brazil — ALERZIN  

Allergic Rhinitis Clinical Trial

Official title: Multicenter,Randomized,Parallel,Double-blind,Double-dummy,Comparative Superiority Study of Levocetirizine 5mg / Pseudoephedrine 240mg From Eurofarma vs Zina®5mg in the Symptomatic of Allergic Rhinitis

Status Not yet recruiting

Clinical Trial Summary

AR is the most common respiratory disease worldwide and is clinically defined by the presence of nasal symptoms induced by exposure to allergens, particularly nasal obstruction and pruritus, runny nose and sneezing. The treatment purpose is to prevent or alleviate symptoms as safely and effectively as possible. Above all, it is recommended that patients avoid contact with allergens to which they are sensitive. However, this is often not enough, and pharmacological interventions are often required. H1 antihistamines (anti-H1) are considered first-line drugs in the treatment of AR1. These drugs effectively relieve symptoms of the immediate phase of AR, such as nasal pruritus, sneezing, runny nose and associated eye symptoms, and partially the nasal blockage characteristic of the late phase of the disease. Due to their excellent safety profile and therapeutic advantages in the treatment of AR, second-generation anti-H1 drugs, such as levocetirizine, should always be prioritized over older compounds in all age groups1. The combined administration of an antihistamine and an oral decongestant was shown to b more effective than the administration of an antihistamine alone for the relief of AR-associated nasal obstruction1. Levocetirizine is an active pharmaceutical ingredient (API) registered in the country as a monodrug for oral administration at a dose of 5mg. Pseudoephedrine is not marketed as a monodrug for oral use in our area, but it is registered in FDC with antihistamines, which is why there is no comparator arm treating with pseudoephedrine only. These products are widely used and their efficacy and safety are well known in daily clinical practice in the proposed indication. Once the absence of a pharmacokinetic interaction between levocetirizine and pseudoephedrine has been confirmed in relative bioavailability studies (RBA), this phase 3 study will be conducted in order to demonstrate the superiority of FDC levocetirizine 5mg / pseudoephedrine 240mg over levocetirizine 5mg administered alone in the symptomatic treatment of AR, particularly with regard to nasal obstruction. The registration seeks to provide a new effective and safe therapeutic option to address these cases.

Clinical Trial Description

The investigational drug consists of a fixed-dose combination (FDC) that contains levocetirizine, a second-generation anti-H1 antihistamine agent, and pseudoephedrine, an oral decongestant, in doses of 5mg and 240mg, respectively, in the dosage form of film-coated tablets. This product is an unprecedented FDC in the country that is indicated for the symptomatic treatment of allergic rhinitis (AR) in patients aged ≥ 12 years. A multicenter, randomized, parallel-group, double-blind, double-dummy, superiority, active-controlled clinical trial. Adolescents and adults (aged ≥ 12 years) of both sexes with intermittent or persistent AR will be randomized in a 1:1 ratio to receive the investigational drug (FDC levocetirizine 5mg / pseudoephedrine 240mg from Eurofarma Laboratórios S.A.) or levocetirizine 5mg (Zina®), once daily (morning), for seven (07) days. The severity of nasal allergy symptoms in the last 24 hours (nasal obstruction, runny nose, sneezing and nasal pruritus) will be evaluated through the application of the assessment questionnaire for nasal symptoms in the last 24 hours before, during and at the end of treatment. The severity of the nasal obstruction at that timepoint will also be evaluated immediately before and one (01) hour after the administration of the first dose of the study treatment, carried out at the research site (also in the morning). Participants will be monitored for an additional seven (07) days for safety assessment. ;

Related Conditions & MeSH terms

• Allergic Rhinitis
• Rhinitis
• Rhinitis, Allergic

• NCT number: NCT05637710
• Study type: Interventional
• Source: Eurofarma Laboratorios S.A.
• Contact: Edilene Macedo
• Phone: 5511 5090-8422
• Email: edilene.macedo@eurofarma.com
• Status: Not yet recruiting
• Phase: Phase 3
• Start date: May 30, 2025
• Completion date: August 30, 2026